Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 2/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23880545 | 1.00 | TLR2 (0.39) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL30509100 | 1.00 | TLR2 (0.39) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL84146 | 0.99 | TLR2 (0.39) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL29077872 | 0.94 | PTPN1 (0.44) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL29077869 | 0.94 | PTPN1 (0.44) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL29077921 | 0.94 | PTPN1 (0.44) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL29077866 | 0.94 | PTPN1 (0.44) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL29077936 | 0.94 | PTPN1 (0.44) | TLR2KMT2AMAP1LC3BPTPN1CASP3 | |
| SCHEMBL29609021 | 0.94 | PTPN1 (0.39) | TLR2KMT2AMAP1LC3BPTPN1FURIN | |
| SCHEMBL29608650 | 0.94 | PTPN1 (0.39) | TLR2KMT2AMAP1LC3BPTPN1FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240252661-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4406608-A2 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252661-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | TLR2 4616/4885KMT2A 1644/4885MAP1LC3B 2750/4885 |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | FOLH1, TGM2, SLC3A2 | TLR2 4172/4885KMT2A 1200/4885MAP1LC3B 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.